185 related articles for article (PubMed ID: 28934640)
1. Continuous longitudinal infusion of rhIGF-1/rhIGFBP-3 in extremely preterm infants: Evaluation of feasibility in a phase II study.
Hansen-Pupp I; Hellström A; Hamdani M; Tocoian A; Kreher NC; Ley D; Hallberg B
Growth Horm IGF Res; 2017 Oct; 36():44-51. PubMed ID: 28934640
[TBL] [Abstract][Full Text] [Related]
2. Elevated levels of IL-6 and IGFBP-1 predict low serum IGF-1 levels during continuous infusion of rhIGF-1/rhIGFBP-3 in extremely preterm infants.
Klevebro S; Hellgren G; Hansen-Pupp I; Wackernagel D; Hallberg B; Borg J; Pivodic A; Smith L; Ley D; Hellström A
Growth Horm IGF Res; 2020 Feb; 50():1-8. PubMed ID: 31756675
[TBL] [Abstract][Full Text] [Related]
3. Development and verification of a pharmacokinetic model to optimize physiologic replacement of rhIGF-1/rhIGFBP-3 in preterm infants.
Chung JK; Hallberg B; Hansen-Pupp I; Graham MA; Fetterly G; Sharma J; Tocoian A; Kreher NC; Barton N; Hellström A; Ley D
Pediatr Res; 2017 Mar; 81(3):504-510. PubMed ID: 27870826
[TBL] [Abstract][Full Text] [Related]
4. rhIGF-1/rhIGFBP-3 in Preterm Infants: A Phase 2 Randomized Controlled Trial.
Ley D; Hallberg B; Hansen-Pupp I; Dani C; Ramenghi LA; Marlow N; Beardsall K; Bhatti F; Dunger D; Higginson JD; Mahaveer A; Mezu-Ndubuisi OJ; Reynolds P; Giannantonio C; van Weissenbruch M; Barton N; Tocoian A; Hamdani M; Jochim E; Mangili A; Chung JK; Turner MA; Smith LEH; Hellström A;
J Pediatr; 2019 Mar; 206():56-65.e8. PubMed ID: 30471715
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety.
Ley D; Hansen-Pupp I; Niklasson A; Domellöf M; Friberg LE; Borg J; Löfqvist C; Hellgren G; Smith LE; Hård AL; Hellström A
Pediatr Res; 2013 Jan; 73(1):68-74. PubMed ID: 23095978
[TBL] [Abstract][Full Text] [Related]
6. Safety aspects of longitudinal administration of IGF-I/IGFBP-3 complex in neonatal mice.
Hellgren G; Han W; Wang X; Löfqvist C; Hagberg H; Mallard C; Hellström A
Growth Horm IGF Res; 2011 Aug; 21(4):205-11. PubMed ID: 21696987
[TBL] [Abstract][Full Text] [Related]
7. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.
Clemmons DR; Sleevi M; Allan G; Sommer A
J Clin Endocrinol Metab; 2007 Jul; 92(7):2652-8. PubMed ID: 17426090
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
[TBL] [Abstract][Full Text] [Related]
9. Pilot dose-ranging of rhIGF-1/rhIGFBP-3 in a preterm lamb model of evolving bronchopulmonary dysplasia.
Albertine KH; Dahl MJ; Rebentisch A; Dawson E; Nabi A; Bowen S; Miers C; Wang Z; Yang H; Yu B; Null DM; Keefe D; Chung JK; Zhou Z; Barton N; Carey G; Ward R
Pediatr Res; 2023 May; 93(6):1528-1538. PubMed ID: 36030318
[TBL] [Abstract][Full Text] [Related]
10. Randomized Control Trial of Postnatal rhIGF-1/rhIGFBP-3 Replacement in Preterm Infants:
Horsch S; Parodi A; Hallberg B; Malova M; Björkman-Burtscher IM; Hansen-Pupp I; Marlow N; Beardsall K; Dunger D; van Weissenbruch M; Smith LEH; Hamdani M; Mangili A; Barton N; Ramenghi LA; Hellström A; Ley D;
Front Pediatr; 2020; 8():517207. PubMed ID: 33163463
[No Abstract] [Full Text] [Related]
11. A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants.
Löfqvist C; Niklasson A; Engström E; Friberg LE; Camacho-Hübner C; Ley D; Borg J; Smith LE; Hellström A
Pediatr Res; 2009 May; 65(5):574-9. PubMed ID: 19190540
[TBL] [Abstract][Full Text] [Related]
12. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.
Clemmons DR; Moses AC; Sommer A; Jacobson W; Rogol AD; Sleevi MR; Allan G
Growth Horm IGF Res; 2005 Aug; 15(4):265-74. PubMed ID: 16005252
[TBL] [Abstract][Full Text] [Related]
13. Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex.
Guha N; Erotokritou-Mulligan I; Bartlett C; Nevitt SP; Francis M; Bassett EE; Cowan DA; Sönksen PH; Holt RI
J Clin Endocrinol Metab; 2014 Jun; 99(6):2259-68. PubMed ID: 24606087
[TBL] [Abstract][Full Text] [Related]
14. Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1.
Heatwole CR; Eichinger KJ; Friedman DI; Hilbert JE; Jackson CE; Logigian EL; Martens WB; McDermott MP; Pandya SK; Quinn C; Smirnow AM; Thornton CA; Moxley RT
Arch Neurol; 2011 Jan; 68(1):37-44. PubMed ID: 20837825
[TBL] [Abstract][Full Text] [Related]
15. Insulin-Like Growth Factor 1 in the Preterm Rabbit Pup: Characterization of Cerebrovascular Maturation following Administration of Recombinant Human Insulin-Like Growth Factor 1/Insulin-Like Growth Factor 1-Binding Protein 3.
Gram M; Ekström C; Holmqvist B; Carey G; Wang X; Vallius S; Hellström W; Ortenlöf N; Agyemang AA; Smith LEH; Hellström A; Mangili A; Barton N; Ley D
Dev Neurosci; 2021; 43(5):281-295. PubMed ID: 34218224
[TBL] [Abstract][Full Text] [Related]
16. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
[TBL] [Abstract][Full Text] [Related]
17. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
[TBL] [Abstract][Full Text] [Related]
18. IGF-1 as a Drug for Preterm Infants: A Step-Wise Clinical Development.
Hellstrom A; Ley D; Hallberg B; Lofqvist C; Hansen-Pupp I; Ramenghi LA; Borg J; Smith LEH; Hard AL
Curr Pharm Des; 2017; 23(38):5964-5970. PubMed ID: 28969546
[TBL] [Abstract][Full Text] [Related]
19. Development of Protein-Specific Analytical Methodologies to Evaluate Compatibility of Recombinant Human (rh)IGF-1/rhIGFBP-3 with Intravenous Medications Co-Administered to Neonates.
Salamat-Miller N; Qu W; Chadwick JS; McPherson C; Salinas PA; Turner M; Wang D; Barton N
J Pharm Sci; 2022 May; 111(5):1486-1496. PubMed ID: 34717953
[TBL] [Abstract][Full Text] [Related]
20. Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
Holt RI; Guha N; Böhning W; Bartlett C; Cowan DA; Sönksen PH; Böhning D
Drug Test Anal; 2017 Jan; 9(1):30-37. PubMed ID: 26888146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
